55 PARK LANE, LONDON, X0
To Present at BIO-Europe 2025 in Vienna
Chairman and Founder Acquires Shares
Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
To Present at the GPCRs-Targeted Drug Discovery Summit
FDA Grants Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
Amended Annual and Transition Report of Foreign Private Issuers
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
No filings found
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
NT 20-F
Free Writing Prospectus
Correspondence